Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double‐Blind, Randomized, Placebo‐Controlled Trial

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Their role in patients without heart failure, particularly in patients with coronary artery disease (CAD) and preserved EF, is still a matter of debate. H...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cardiol
Hlavní autoři: Sudano, Isabella, Naegele, Matthias, Roas, Susanne, Périat, Daniel, Frank, Michelle, Kouroedov, Alexey, Noll, Georg, Lüscher, Thomas F., Enseleit, Frank, Ruschitzka, Frank, Flammer, Andreas J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley Periodicals, Inc. 2016
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6490773/
https://ncbi.nlm.nih.gov/pubmed/26991772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22528
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky